Aurinia To Present Six Abstracts, Including Five Poster Presentations, At The American Society Of Nephrology Kidney Week 2024 Taking Place In San Diego, October 23-27
Aurinia To Present Six Abstracts, Including Five Poster Presentations, At The American Society Of Nephrology Kidney Week 2024 Taking Place In San Diego, October 23-27
Aurinia將在2024年10月23-27日在聖迭戈舉行的美國腎臟病學學會腎周活動上提交六個摘要，包括五個海報展示。
These data reinforce the clinical importance of LUPKYNIS (voclosporin), a second generation calcineurin inhibitor (CNI), for the treatment of adults with active lupus nephritis (LN).
這些數據強化了LUPKYNIS（voclosporin）作爲第二代鈣調神經酶抑制劑（證券龍頭）對治療活動性狼瘡性腎炎（LN）成年患者的臨床重要性。
This initial analysis of baseline data from 123 patients with biopsy-confirmed LN who are initiating or have initiated treatment with LUPKYNIS within the last 12 months provides a critical foundation for understanding the real-world effectiveness and usage patterns of LUPKYNIS.
這項123名通過活檢確認患有LN的患者的基線數據的初始分析，這些患者正在或已經在過去12個月內開始或已經接受LUPKYNIS治療，爲理解LUPKYNIS的真實世界有效性和使用模式提供了關鍵基礎。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
資訊熱榜
更新時間